-1750795099217.webp&w=3840&q=75)
2025 MLS Nashville | CLL/Lymphoma Updates
Overview
Dr. Jallouk’s ASCO update showed that in TP53‑mutated CLL, zanubrutinib delivered five‑year PFS of 72 % and OS of 85.1 % in SEQUOIA, with zanubrutinib + venetoclax achieving even deeper, MRD‑negative responses. He also reported STARGLO’s significant PFS/OS gains for the glofitamab‑GemOx regimen in large B‑cell lymphoma, although the FDA’s ODAC voted against approval because of pronounced geographic heterogeneity, notably in U.S. patients.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Andrew Jallouk, MD
Date of Release
June 25th, 2025
